n January 26, 2021 Shaperon reported that it had signed a memorandum of understanding (MOU) with Selvion for cooperation in the joint development of new drugs for diagnosis and treatment of cancer (Press release, Shaperon, JAN 26, 2021, View Source;idx=38&pNo=3&code=press_en [SID1234629323]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Based on precision medicine technology, Cellvion is a bio company that is conducting clinical trials and development of new drugs such as medicines for diagnosis and treatment of intravascular inflammation, specific cancer, and complex contrast media for imaging surgery with leading university hospitals in Korea. We have production facilities that have obtained GMP (Good Manufacturing Practice) approval from the Ministry of Safety and Security.
In addition, in August, it obtained QP certification from the European EMA, and produced and supplied GMP clinical trial drugs to be used in the European phase 2 clinical trial of Chaperone’s COVID-19 treatment.
Through this agreement, Chaperon plans to accelerate the development of new drugs for diagnosing and treating cancer diseases, such as nanobody-based positron emission tomography (PET) diagnostic radiopharmaceuticals.
Chaperon’s own nanobody antibody technology has high antigen binding ability and stability as well as low immunogenicity, so it is attracting attention as a next-generation antibody treatment for the development of complex antibodies.
Based on this, Chaperone plans to develop a radiopharmaceutical diagnostic agent for PET diagnosis by applying nanobody technology targeting cancer cells or specific T-cell markers to determine the drug for immuno-anticancer drug treatment and determine whether to continue treatment with Cellvion.
In addition, the two companies plan to jointly conduct research and development of oral mucositis treatment mixed with ‘HY209’, which is currently being developed as a new drug candidate for atopic dermatitis.
Lee Myung-se, CEO of Chaperon, said, "We expect to accelerate the research and development of our nanobody antibody-based technology and inflammatory complex inhibitor new drug candidates through cooperation with Cellvion, which has excellent precision medicine technology."
Cellvion CEO Kwon Kim said, "We are sincerely pleased to have signed an MOU with Chaperone, which is leading the development of fundamental treatments for inflammatory and immune diseases, and expect that this agreement will fully exert synergy for the development of new drugs for diagnosis and treatment of cancer diseases. "he said.
Meanwhile, Chaperon is leading the research and development of inflammatory and immune disease treatments based on the theory of DAMPs (Damage-Associated Molecular Patterns) presented by CEO Seung-yong Sung for the first time in the world in ‘Nature Review Immunology,’ a world-renowned academic journal in the field of immunology. It is a bio-venture company.
In September 2020, Chaperone successfully attracted a series C investment of KRW 26 billion, and will lead the next-generation bio field as well as a new mechanism of inflammatory complex inhibitor for the treatment of major inflammatory diseases such as atopic dermatitis, Alzheimer’s disease, and ulcerative colitis. It is expanding its pipeline in various fields, including nanobody antibody-based immuno-oncology drugs.